Cannabidiolic acid prevents vomiting in Suncus murinus and nausea‐induced behaviour in rats by enhancing 5‐HT1A receptor activation

To evaluate the ability of cannabidiolic acid (CBDA) to reduce nausea and vomiting and enhance 5‐HT1A receptor activation in animal models.

[1]  R. Pertwee.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. , 2008, British journal of pharmacology.

[2]  R. Stern,et al.  The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness. , 2000, Aviation, space, and environmental medicine.

[3]  W. Johnson,et al.  Importance of the vestibular system in visually induced nausea and self-vection. , 1999, Journal of vestibular research : equilibrium & orientation.

[4]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[5]  R. Mechoulam,et al.  A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew) , 2004, Psychopharmacology.

[6]  C. Wilpizeski,et al.  Motion‐Induced Sickness Following Bilateral Ablation of Area Postrema in Squirrel Monkeys , 1986, The Laryngoscope.

[7]  I. Howard,et al.  Visually-induced sickness in normal and bilaterally labyrinthine-defective subjects. , 1991, Aviation, space, and environmental medicine.

[8]  L. Parker.  Taste avoidance and taste aversion: Evidence for two different processes , 2003, Learning & behavior.

[9]  A GRAYBIEL,et al.  XXIV Effects of Labyrinthectomy on Canal Sickness in Squirrel Monkey , 1962, The Annals of otology, rhinology, and laryngology.

[10]  R. Pertwee,et al.  Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist , 2005, British journal of pharmacology.

[11]  J T Reason,et al.  Motion Sickness Adaptation: A Neural Mismatch Model 1 , 1978, Journal of the Royal Society of Medicine.

[12]  J. Foubert,et al.  Nausea: the neglected symptom? , 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[13]  H. Grill,et al.  The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats , 1978, Brain Research.

[14]  T. Bisogno,et al.  Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes , 2011, British journal of pharmacology.

[15]  David J Potter,et al.  Potency of Δ9–THC and Other Cannabinoids in Cannabis in England in 2005: Implications for Psychoactivity and Pharmacology * , 2008, Journal of forensic sciences.

[16]  C. Limebeer,et al.  Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. , 2008, Canadian journal of experimental psychology = Revue canadienne de psychologie experimentale.

[17]  R. Mechoulam,et al.  Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea , 2003, Psychopharmacology.

[18]  R. Naylor,et al.  The effect of the 5-HT1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus , 2006, Pharmacology Biochemistry and Behavior.

[19]  R. Naylor,et al.  The effects of cannabidiolic acid and cannabidiol on contractility of the gastrointestinal tract of Suncus murinus , 2011, Archives of pharmacal research.

[20]  R. Mechoulam,et al.  Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew) , 2003, Psychopharmacology.

[21]  F. Guimarães,et al.  Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats , 2008, Psychopharmacology.

[22]  D. Piomelli,et al.  The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat , 2008, Psychopharmacology.

[23]  C. C. Horn,et al.  Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[24]  R. Pertwee.  The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids : D 9-tetrahydrocannabinol , cannabidiol and D 9-tetrahydrocannabivarin , 2007 .

[25]  K. Abe,et al.  Cannabidiol Prevents Cerebral Infarction Via a Serotonergic 5-Hydroxytryptamine1A Receptor–Dependent Mechanism , 2005, Stroke.

[26]  R. Pertwee,et al.  Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro , 2007, British journal of pharmacology.

[27]  I. Yamamoto,et al.  Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis , 2008, Drug Metabolism and Disposition.

[28]  C. Kilkenny,et al.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines , 2010, British journal of pharmacology.

[29]  H. Grill,et al.  Chronically decerebrate rats demonstrate satiation but not bait shyness. , 1978, Science.

[30]  J. Martínez-Orgado,et al.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? , 2013, British journal of clinical pharmacology.

[31]  R S Kennedy,et al.  Symptomatology under storm conditions in the North Atlantic in control subjects and in persons with bilateral labyrinthine defects. , 1968, Acta oto-laryngologica.

[32]  M. Qazilbash,et al.  Clinical Efficacy of Lorazepam in Prophylaxis of Anticipatory, Acute, and Delayed Nausea and Vomiting Induced by High Doses of Cisplatin: A Prospective Randomized Trial , 1995, American journal of clinical oncology.

[33]  F. Roila,et al.  Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy , 2003, Health and quality of life outcomes.

[34]  J. Atkins,et al.  Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics , 2003, Cancer.

[35]  G R Barnes,et al.  The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties. , 1989, British journal of clinical pharmacology.

[36]  C. Limebeer,et al.  Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews , 2011, Psychopharmacology.

[37]  P. C. Karlsson,et al.  Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. , 2011, Biological & pharmaceutical bulletin.

[38]  F. Piscitelli,et al.  Non‐psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action , 2011, British journal of pharmacology.

[39]  K. Money,et al.  THE ROLE OF THE SEMICIRCULAR CANALS IN CAUSATION OF MOTION SICKNESS AND NYSTAGMUS IN THE DOG. , 1964, Canadian journal of physiology and pharmacology.

[40]  C. Limebeer,et al.  Cannabinoids in the Management of Nausea and Vomiting , 2008 .

[41]  G. Nomikos,et al.  WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation , 2003, Behavioural Brain Research.

[42]  K. Ossenkopp,et al.  Rotation-induced conditioned rejection in the taste reactivity test. , 1999, Neuroreport.

[43]  P. Fletcher,et al.  Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleus , 2012, British journal of pharmacology.

[44]  V. Vellani,et al.  Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[45]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[46]  C. Limebeer,et al.  Inverse agonism of cannabinoid CB1 receptors potentiates LiCl‐induced nausea in the conditioned gaping model in rats , 2010, British journal of pharmacology.

[47]  K. Ossenkopp,et al.  Vestibular lesions selectively abolish body rotation-induced, but not lithium-induced, conditioned taste aversions (oral rejection responses) in rats. , 2003, Behavioral neuroscience.

[48]  G. Hall,et al.  Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea , 2006, Physiology & Behavior.

[49]  R. Pertwee,et al.  6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. , 2004, European journal of pharmacology.

[50]  A. Chaudhury,et al.  Brain Fos expression during 48 h after cisplatin treatment: Neural pathways for acute and delayed visceral sickness , 2007, Autonomic Neuroscience.

[51]  R. Kennedy,et al.  Symptomatology under storm conditions in the North Atlantic in control subjects and in persons with bilateral labyrinthine defects. NSAM-928. , 1965, Research report. Naval School of Aviation Medicine.

[52]  G. Morrow,et al.  Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics , 1998, Supportive Care in Cancer.

[53]  C. Limebeer,et al.  Effect of Δ9-tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test , 2005, Physiology & Behavior.

[54]  R. Naylor,et al.  The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. , 2008, Basic & clinical pharmacology & toxicology.

[55]  R. Mechoulam,et al.  Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. , 1965, Tetrahedron.

[56]  J. Verweij,et al.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.

[57]  C. Biojone,et al.  Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1A receptors , 2010, British journal of pharmacology.

[58]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[59]  R. Nesse,et al.  Pretreatment Nausea in Cancer Chemotherapy: A Conditioned Response?* , 1980, Psychosomatic medicine.

[60]  A. Pastor,et al.  Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. , 2010, British journal of clinical pharmacology.

[61]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[62]  K. Ossenkopp,et al.  Exposure to a context previously associated with nausea elicits conditioned gaping in rats: A model of anticipatory nausea , 2008, Behavioural Brain Research.

[63]  R. Pertwee,et al.  Structural determinants of the partial agonist‐inverse agonist properties of 6′‐azidohex‐2′‐yne‐Δ8‐tetrahydrocannabinol at cannabinoid receptors , 1999, British journal of pharmacology.

[64]  A. Irving,et al.  Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids* , 2011, The Journal of Biological Chemistry.

[65]  J. Vredenburgh,et al.  Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting* , 2007, Current medical research and opinion.

[66]  R Shaker,et al.  Gastrointestinal motor and myoelectric correlates of motion sickness. , 1999, The American journal of physiology.

[67]  F. Guimarães,et al.  The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors , 2011, Psychopharmacology.